E Ink participated in the $42.5m first tranche of the gene and protein-focused 3D printing technology developer’s latest round having worked with it on a digital microfluidic tool called eDrop.
UK-based bioprinting technology developer Nuclera reached a $42.5m first close for its series B round yesterday that included electronic paper display producer E Ink, as additive manufacturing gains more attention in the pharmaceutical industry.
State-owned financial services firm British Business Bank’s Future Fund also took part in the round, as did M&G Investments, Amadeus Capital Partners, RT Partners, Future Planet Capital and G K Goh Holdings.
Founded in 2013 by three PhD students at University of Cambridge, Nuclera is working…
